Tumor microenvironment of soft tissue sarcomas: emerging opportunities for prognosis and therapy

Soft tissue sarcomas (STS) are a heterogeneous group of mesenchymal malignancies comprising over 50 histological subtypes. Despite their rarity, these tumors are characterized by aggressive clinical behavior, high metastatic potential, and limited sensitivity to conventional systemic therapies. Accumulating evidence highlights the pivotal role of the tumor microenvironment in STS progression, prognosis, and treatment response. The composition of the immune infiltrate – including tumor-associated macrophages, T and B lymphocytes, and tertiary lymphoid structures – varies substantially across histological subtypes and determines both tumor biology and susceptibility to immunotherapy. The discovery of the prognostic and predictive significance of tertiary lymphoid structures and B-cell infiltration in STS has been one of the most important advances in the field. Immune checkpoint inhibitors have shown clinical activity in select subtypes, including undifferentiated pleomorphic sarcoma, angiosarcoma, and alveolar soft part sarcoma, although overall response rates remain modest. Combination strategies integrating immune checkpoint inhibitors with antiangiogenic agents, chemotherapy, or radiation therapy, as well as adoptive cellular therapies using engineered T-cell receptors, are opening new avenues for personalized treatment. This review systematizes current knowledge on the cellular and molecular composition of the STS microenvironment, its prognostic significance, and emerging therapeutic opportunities.

Authors

Institutions

Publication Details

Journal
MD-Onco
Published
2026-11-17
DOI
https://doi.org/10.17650/2782-3202-2026-6-3-21-28
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Tumor microenvironment of soft tissue sarcomas: emerging opportunities for prognosis and therapy

Dmitry V. Bulanov, D. R. Makhachev, I. G. Musapirov, M. O. Abakarov et al.
MD-Onco
Sarcoma Diagnosis and Treatment
article

Tumor microenvironment of soft tissue sarcomas: emerging opportunities for prognosis and therapy

Dmitry V. Bulanov, D. R. Makhachev, I. G. Musapirov, M. O. Abakarov, R. A. Abramenko, A. R. Gasanov, Dzhabrailova Umuraziyat Abdullaevna, Mikailova Samira Aminullaevna, Uyutnova Anna Vladimirovna, Timryazansky Aleksey Stanislavovich, Sandzhigoryaeva Alexandra Dordzhievna
article en

Abstract

Soft tissue sarcomas (STS) are a heterogeneous group of mesenchymal malignancies comprising over 50 histological subtypes. Despite their rarity, these tumors are characterized by aggressive clinical behavior, high metastatic potential, and limited sensitivity to conventional systemic therapies. Accumulating evidence highlights the pivotal role of the tumor microenvironment in STS progression, prognosis, and treatment response. The composition of the immune infiltrate – including tumor-associated macrophages, T and B lymphocytes, and tertiary lymphoid structures – varies substantially across histological subtypes and determines both tumor biology and susceptibility to immunotherapy. The discovery of the prognostic and predictive significance of tertiary lymphoid structures and B-cell infiltration in STS has been one of the most important advances in the field. Immune checkpoint inhibitors have shown clinical activity in select subtypes, including undifferentiated pleomorphic sarcoma, angiosarcoma, and alveolar soft part sarcoma, although overall response rates remain modest. Combination strategies integrating immune checkpoint inhibitors with antiangiogenic agents, chemotherapy, or radiation therapy, as well as adoptive cellular therapies using engineered T-cell receptors, are opening new avenues for personalized treatment. This review systematizes current knowledge on the cellular and molecular composition of the STS microenvironment, its prognostic significance, and emerging therapeutic opportunities.

MD-OncoVol. 6(3)
Pirogov Russian National Research Medical University (RU), Ministry of Health of the Russian Federation (RU)
Sarcoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon